查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1771486

帶狀皰疹疫苗市場規模、佔有率、趨勢分析報告（按產品類型、疫苗類型、最終用途、地區、細分市場預測），2025 年至 2030 年

Shingles Vaccine Market Size, Share & Trends Analysis Report By Product, By Vaccine Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

帶狀皰疹疫苗市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球帶狀皰疹疫苗市場規模預計到2030年將達到112.6億美元，2025年至2030年的複合年成長率為15.7%。已開發國家帶狀皰疹發病率的上升以及人們對帶狀皰疹的認知度的提高，推動了市場規模的擴張。根據美國疾病管制與預防中心(CDC)統計，美國每年通報近一百萬例帶狀皰疹病例。此外，美國三分之一的人一生中都會患上這種疾病。

預計疫苗接種率的提高以及各政府監管機構不斷增加的疫苗接種建議將在預測期內推動市場發展。例如，2019年2月，英國疫苗接種聯合委員會(JCVI)建議60-70歲成年人使用重組疫苗預防帶狀皰疹。

帶狀皰疹疫苗被納入多個國家的國家免疫計劃，預計將推動該疫苗的需求。例如，自2013年以來，帶狀皰疹疫苗一直是英國國家免疫計畫的一部分。英國是歐洲地區第一個將帶狀皰疹疫苗納入國家免疫計畫的國家，一劑疫苗的費用約為國家醫療服務體系（NHS）的130美元。同樣，美國、義大利、澳洲、加拿大多個省份和韓國等其他國家也已將該疫苗納入其免疫計畫。

此外，市場相關人員和監管機構為提高患有該疾病風險族群的認知度而採取的積極措施預計將在未來幾年推動市場成長。例如，葛蘭素史克公司發起了宣傳活動，透過教育人們了解疫苗接種的益處來提高老年人的疫苗接種率。

由於該疫苗的高效性，預計在預測期內將廣泛應用。臨床試驗結果表明， 定序在預防帶狀皰疹和帶狀皰疹後遺症神經痛方面非常有效。兩劑定序對 50 歲及以上成年人的帶狀皰疹預防有效率超過 90%。接種疫苗後，該疫苗的保護效力至少可維持四年，且 85% 以上。

疫苗價格低廉，加上已開發國家的高發病率和疫苗接種覆蓋率，預計將刺激市場成長。英國、美國、法國、加拿大、德國和韓國的帶狀皰疹疫苗接種覆蓋率高於其他國家。例如，英國的帶狀皰疹疫苗接種覆蓋率最高，超過60%的符合條件的成年人接種了疫苗。

帶狀皰疹疫苗市場報告重點

  • 2024 年帶狀皰疹疫苗市場由定序主導，佔最大銷售佔有率，為 94.14%。
  • 2024 年，私人醫療保健組織佔據帶狀皰疹疫苗市場的最大收入佔有率，為 68.33%。
  • 在 2024 年的帶狀皰疹疫苗市場中，重組疫苗佔最大佔有率，收益佔有率為 94.14%。
  • 2024年，北美帶狀皰疹疫苗市場領先全球市場，佔最大收益佔有率，達62.26%。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 帶狀皰疹疫苗市場變數、趨勢和範圍

  • 市場介紹/電網展望
  • 市場規模和成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 帶狀皰疹疫苗市場分析工具
    • 波特分析
    • PESTEL分析

第4章帶狀皰疹疫苗市場：產品類型估計和趨勢分析

  • 細分儀表板
  • 帶狀皰疹疫苗市場：2024 年和 2030 年產品類型變化分析
  • 定序
  • 佐斯塔瓦克斯
  • 天空之星

第5章帶狀皰疹疫苗市場：疫苗類型估計和趨勢分析

  • 細分儀表板
  • 帶狀皰疹疫苗市場：2024 年和 2030 年疫苗類型變化分析
  • 重組疫苗
  • 減毒活疫苗

6. 帶狀皰疹疫苗市場：最終用途預估與趨勢分析

  • 細分儀表板
  • 帶狀皰疹疫苗市場：2024 年和 2030 年按最終用途分類的變化分析
  • 私人醫療保健機構
  • 政府醫療機構

第7章帶狀皰疹疫苗市場：區域估計和趨勢分析

  • 2024 年及 2030 年各地區市場佔有率分析
  • 市場儀表板
  • 市場概述
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司分類
  • 公司熱圖分析
  • 公司簡介
    • GlaxoSmithKline plc.
    • Pfizer Inc.
    • Merck &Co., Inc.
    • CanSinoBIO
    • Vaccitech
    • Green Cross Corp
    • Geneone Life Science
    • SK Bioscience
Product Code: GVR-4-68039-638-0

Shingles Vaccine Market Growth & Trends:

The global shingles vaccine market size is expected to reach USD 11.26 billion by 2030, registering a CAGR of 15.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing incidence of shingles and high awareness regarding shingles in developed countries are contributing to the market growth. According to the CDC, nearly one million cases of shingles are reported each year in the United States. Furthermore, one out of three individuals in the country will develop the disease in their lifetime.

The increasing adoption of vaccines and an increase in the recommendation of vaccination by different government regulatory bodies are expected to drive the market over the forecast period. For instance, in February 2019, the U.K. Joint Committee of Vaccination and Immunization (JCVI) has recommended the use of the recombinant vaccine to prevent shingles in adults aged 60 to 70 years old.

The inclusion of shingles vaccines in national immunization programs of several countries is anticipated to propel the demand for vaccines. For instance, the shingles vaccine is a part of the national immunization program in the U.K. since 2013. The U.K. is the first country in the European region to introduce shingles vaccine in the national immunization program and it costs around USD 130 to the National Health Service (NHS) for each dose of the vaccine. Similarly, other countries such as the U.S., Italy, Australia, and some provinces of Canada and South Korea have also included the vaccine in their immunization program.

Besides, favorable initiatives undertaken by market players and regulatory bodies to increase the awareness among people who are at risk of developing the disease are expected to fuel the market growth over the coming years. For instance, GlaxoSmithKline plc. has launched a campaign to increase vaccination rates among older adults by educating people about the benefits associated with vaccination.

The high efficacy of vaccines is expected to increase the adoption over the forecast period. According to clinical trial results, Shingrix is highly efficient to prevent shingles and postherpetic neuralgia. Two doses of Shingrix are more than 90% effective to prevent the disease in adults aged 50 years and above. Protection stays above 85% for at least the first four years after getting vaccinated.

The availability of vaccines at lower prices, coupled with a high incidence of the disease and high vaccination rate in developed countries, is anticipated to fuel the market growth. The vaccination rate against shingles in the U.K., the U.S., France, Canada, Germany, and South Korea is higher compared to other countries owing to better reimbursement policies and high awareness levels regarding the disease and vaccines. For instance, the U.K. has the highest shingles vaccine uptake with more than 60% vaccination of eligible adults.

Shingles Vaccine Market Report Highlights:

  • The Shingrix segment dominated the shingles vaccine market in 2024, accounting for the largest revenue share of 94.14%.
  • The private healthcare settings segment dominated the shingles vaccine market, accounting for the largest revenue share of 68.33% in 2024.
  • The recombinant vaccine segment accounted for the largest share of the shingles vaccine market in 2024, comprising a revenue share of 94.14%.
  • North America shingles vaccine market led the global market in 2024, holding the largest revenue share of 62.26%

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Shingles Vaccine Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. shingles vaccine Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Shingles Vaccine Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Shingles Vaccine Market: Product Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Shingrix
    • 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Zostavax
    • 4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. SKYZoster
    • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Shingles Vaccine Market: Vaccine Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Shingles Vaccine Market: Vaccine Type Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Recombinant Vaccine
    • 5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Live Attenuated Vaccine
    • 5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Shingles Vaccine Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Shingles Vaccine Market: Type Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Private Healthcare Settings
    • 6.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Government Healthcare Settings
    • 6.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Shingles Vaccine Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. GlaxoSmithKline plc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Pfizer Inc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Merck & Co., Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. CanSinoBIO
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Vaccitech
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Green Cross Corp
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Geneone Life Science
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. SK Bioscience
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Leading Market Players Anticipated to Witness Highest Growth
  • Table 4 Global Shingles Vaccines Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 6 Global Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 7 Global Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 8 North America Shingles Vaccines Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 10 North America Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 11 North America Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 12 U.S Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 13 U.S Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 14 U.S Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 15 Canada Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 16 Canada Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 17 Canada Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 18 Mexico Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 19 Mexico Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 20 Mexico Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 21 Europe Shingles Vaccines Market, By Country, 2018 - 2030 (USD Million)
  • Table 22 Europe Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 23 Europe Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 24 Europe Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 25 UK Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 26 UK Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 27 UK Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 28 Germany Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 29 Germany Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 30 Germany Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 31 France Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 32 France Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 33 France Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 34 Italy Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 35 Italy Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 36 Italy Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 37 Spain Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 38 Spain Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 39 Spain Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 40 Denmark Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 41 Denmark Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 42 Denmark Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 43 Sweden Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 44 Sweden Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 45 Sweden Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 46 Norway Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 47 Norway Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 48 Norway Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Shingles Vaccines Market, By Country, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 53 Japan Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 54 Japan Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 55 Japan Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 56 China Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 57 China Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 58 China Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 59 India Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 60 India Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 61 India Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 62 South Korea Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 63 South Korea Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 64 South Korea Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 65 Australia Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 66 Australia Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 67 Australia Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 68 Thailand Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 69 Thailand Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 70 Thailand Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 71 Latin America Shingles Vaccines Market, By Country, 2018 - 2030 (USD Million)
  • Table 72 Latin America Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 73 Latin America Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 74 Latin America Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 75 Brazil Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 76 Brazil Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 77 Brazil Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 78 Argentina Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 79 Argentina Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 80 Argentina Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 81 Middle East and Africa Shingles Vaccines Market, By Country, 2018 - 2030 (USD Million)
  • Table 82 Middle East and Africa Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 83 Middle East and Africa Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 85 South Africa Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 86 South Africa Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 87 South Africa Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 91 UAE Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 92 UAE Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 93 UAE Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Shingles Vaccine market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot-1
  • Fig. 14 Segment snapshot-2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Shingles Vaccine market: Product outlook key takeaways
  • Fig. 20 Shingles Vaccine market: Product movement analysis
  • Fig. 21 Shingrix market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 22 Zostavax market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 23 SKYZoster market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 24 Shingles Vaccine market: Vaccine Type outlook key takeaways
  • Fig. 25 Shingles Vaccine market: Vaccine Type movement analysis
  • Fig. 26 Recombinant vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 27 Live attenuated vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 28 Shingles Vaccine market: End Use outlook key takeaways
  • Fig. 29 Shingles Vaccine market: End Use movement analysis
  • Fig. 30 Private healthcare settings market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 31 Government healthcare settings market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 32 Regional marketplace outlook, 2024 & 2030 (USD million)
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 North America shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 35 Key country dynamics
  • Fig. 36 U.S. shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 37 Key country dynamics
  • Fig. 38 Canada shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 39 Key country dynamics
  • Fig. 40 Mexico shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 41 Europe shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 42 Key country dynamics
  • Fig. 43 UK shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Germany shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 46 Key country dynamics
  • Fig. 47 France shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Spain shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Italy shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Denmark shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Sweden shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Norway shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 58 Asia Pacific shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Japan shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 61 Key country dynamics
  • Fig. 62 China shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 63 Key country dynamics
  • Fig. 64 India shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Australia shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 67 Key country dynamics
  • Fig. 68 South Korea shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Thailand shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 71 Key country dynamics
  • Fig. 72 Latin America shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Brazil shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Argentina shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Middle East & Africa shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 79 Key country dynamics
  • Fig. 80 South Africa shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Saudi Arabia shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 83 Key country dynamics
  • Fig. 84 UAE shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 85 Key country dynamics
  • Fig. 86 Kuwait shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 87 Market participant categorization
  • Fig. 88 Shingles vaccine market position analysis, 2024
  • Fig. 89 Strategic framework